




RealRate

PHARMACEUTICAL 2015

Celgene CORP DE
Rank 161 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Celgene CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celgene CORP DE compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Celgene CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 244%, being 9.6% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	9,712,600
Cost of Goods Sold	0
Intangible Assets	6,258,800
Liabilities, Current	2,112,200
Liabilities, Non-Current	7,846,800
Other Assets	726,100
Other Compr. Net Income	820,800
Other Expenses	1,196,500
Other Liabilities	856,300
Other Net Income	-15,500
Other Revenues	7,670,400
Property and Equipment	642,600
Research and Development	2,430,600
Selling, General and Administrative Expense	2,027,900

Output Variable	Value in 1000 USD
Assets	17,340,100
Liabilities	10,815,300
Expenses	5,655,000
Revenues	7,670,400
Stockholders Equity	6,524,800
Net Income	1,999,900
Comprehensive Net Income	2,410,300
BaseVar	21,158,550
ECR before LimitedLiability	118%
Economic Capital Ratio	244%